Hyperleukocytosis from arsenic trioxide

Pediatr Blood Cancer. 2008 Jun;50(6):1265-7. doi: 10.1002/pbc.21532.

Abstract

We report the case of a 14-year-old male treated with arsenic trioxide for recurrent acute promyelocytic leukemia. He developed hyperleukocytosis (WBC 111.6 x 10(9)/L) which then resolved while continuing daily arsenic. Hyperleukocytosis without other complications may not be an indication for adding cytotoxic therapy or steroids, nor for discontinuing arsenic trioxide therapy in children.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Arsenic Trioxide
  • Arsenicals / adverse effects*
  • Arsenicals / therapeutic use
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukocytosis / chemically induced*
  • Male
  • Oxides / adverse effects*
  • Oxides / therapeutic use
  • Recurrence

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Arsenic Trioxide